Mankind Pharma has reported a 39.2% year-on-year rise in consolidated net profit to Rs 712 crore for the second quarter of FY27, up from Rs 511.5 crore a year earlier, CNBC-TV18 reported. Revenue from operations increased 17.3% to Rs 4,338 crore from Rs 3,697.16 crore in the year-ago quarter.

Source: CNBC-TV18 via 7Globe

Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 27.1% to Rs 1,171 crore from Rs 921.3 crore, and the EBITDA margin improved to 27% from 24.9% a year earlier, as earnings growth outpaced revenue growth on disciplined cost management and a richer product mix, Voice of Healthcare reported.

Source: Voice of Healthcare

Vice Chairman and Managing Director Rajeev Juneja said the domestic business grew 15.9% in the quarter, with volume growth at 1.2 times the growth of the Indian Pharmaceutical Market. The chronic portfolio grew 1.1 times faster than the market, led by 19% growth in cardiac and 16% in anti-diabetes, while the acute portfolio was supported by 19% growth in gastro and 26% in the VMN segment, CNBC-TV18 reported.

Source: CNBC-TV18 via 7Globe

The domestic specialty business of Bharat Serums and Vaccines (BSV) recorded steady double-digit growth and the international business grew 33% during the quarter. The consumer healthcare business, however, reported muted growth of 1.2% amid slower category offtake, even as the share of modern trade and e-commerce in that business rose to 18% from 12% a year earlier, CNBC-TV18 reported.

Source: CNBC-TV18 via 7Globe

Juneja also highlighted the acquisition of Armed Cell Therapeutics, which marks Mankind's entry into next-generation CAR-T therapies. Separately, the board approved a scheme to merge wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the parent, with an appointed date of April 1, 2027, subject to statutory and regulatory approvals including the National Company Law Tribunal where required, Voice of Healthcare reported.

Source: Voice of Healthcare

For the first half of FY27, revenue from operations stood at Rs 8,368 crore, up 15.1% year-on-year, with domestic revenue up 12.7% to Rs 7,082 crore and exports up 31% to Rs 1,286 crore. Shares of the company surged more than 8% in trade on October 27, pushing its market valuation back past Rs 1 lakh crore, CNBC-TV18 and market reports said.

Source: CNBC-TV18 via 7Globe